You are here

  • Home
  • Cyclophosphamide

Cyclophosphamide

  • Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
    Rachel B Jones, Thomas F Hiemstra, Jose Ballarin, Daniel Engelbert Blockmans, Paul Brogan, Annette Bruchfeld, Maria C Cid, Karen Dahlsveen, Janak de Zoysa, Georgína Espigol-Frigolé, Peter Lanyon, Chen Au Peh, Vladimir Tesar, Augusto Vaglio, Michael Walsh, Dorothy Walsh, Giles Walters, Lorraine Harper, David Jayne
    Annals of the Rheumatic Diseases Jan 2019, annrheumdis-2018-214245; DOI: 10.1136/annrheumdis-2018-214245
  • Response to: ’Not all drugs (and routes) are same' by Zanwar and Gandhi
    Pierre Charles, Loic Guillevin
    Annals of the Rheumatic Diseases Jun 2018, annrheumdis-2018-213742; DOI: 10.1136/annrheumdis-2018-213742
  • Update of EULAR recommendations for the treatment of systemic sclerosis
    Otylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, Mike Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip Clements, Maurizio Cutolo, Laszlo Czirjak, Nemanja Damjanov, Francesco del Galdo, Christopher P Denton, Jörg H W Distler, Ivan Foeldvari, Kim Figelstone, Marc Frerix, Daniel E Furst, Serena Guiducci, Nicolas Hunzelmann, Dinesh Khanna, Marco Matucci-Cerinic, Ariane L Herrick, Frank van den Hoogen, Jacob M van Laar, Gabriela Riemekasten, Richard Silver, Vanessa Smith, Alberto Sulli, Ingo Tarner, Alan Tyndall, Joep Welling, Frederic Wigley, Gabriele Valentini, Ulrich A Walker, Francesco Zulian, Ulf Müller-Ladner
    Annals of the Rheumatic Diseases Aug 2017, 76 (8) 1327-1339; DOI: 10.1136/annrheumdis-2016-209909
  • Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
    Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton
    Annals of the Rheumatic Diseases Jul 2017, 76 (7) 1207-1218; DOI: 10.1136/annrheumdis-2016-210503
  • Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
    Emma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, Ron Wolterbeek, Jan A Bruijn, David R Jayne, Ingeborg M Bajema, Chinar Rahmattulla
    Annals of the Rheumatic Diseases Jun 2017, 76 (6) 1064-1069; DOI: 10.1136/annrheumdis-2016-209925
  • EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
    M Yates, R A Watts, I M Bajema, M C Cid, B Crestani, T Hauser, B Hellmich, J U Holle, M Laudien, M A Little, R A Luqmani, A Mahr, P A Merkel, J Mills, J Mooney, M Segelmark, V Tesar, K Westman, A Vaglio, N Yalçındağ, D R Jayne, C Mukhtyar
    Annals of the Rheumatic Diseases Sep 2016, 75 (9) 1583-1594; DOI: 10.1136/annrheumdis-2016-209133
  • Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
    Sebastian Unizony, Miguel Villarreal, Eli M Miloslavsky, Na Lu, Peter A Merkel, Robert Spiera, Philip Seo, Carol A Langford, Gary S Hoffman, CG M Kallenberg, E William St. Clair, David Ikle, Nadia K Tchao, Linna Ding, Paul Brunetta, Hyon K Choi, Paul A Monach, Fernando Fervenza, John H Stone, Ulrich Specks
    Annals of the Rheumatic Diseases Jun 2016, 75 (6) 1166-1169; DOI: 10.1136/annrheumdis-2015-208073
  • Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
    Md Yuzaiful Md Yusof, Edward M Vital, Sudipto Das, Shouvik Dass, Gururaj Arumugakani, Sinisa Savic, Andrew C Rawstron, Paul Emery
    Annals of the Rheumatic Diseases Sep 2015, 74 (9) 1734-1738; DOI: 10.1136/annrheumdis-2014-206496
  • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
    Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, Thomas Hauser, Raashid Luqmani, Matthew D Morgan, Chen Au Peh, Caroline O Savage, Marten Segelmark, Vladimir Tesar, Pieter van Paassen, Michael Walsh, Kerstin Westman, David RW Jayne, for the European Vasculitis Society (EUVAS)
    Annals of the Rheumatic Diseases Jun 2015, 74 (6) 1178-1182; DOI: 10.1136/annrheumdis-2014-206404
  • Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
    Cees G M Kallenberg
    Annals of the Rheumatic Diseases Apr 2013, 72 (suppl 2) ii62-ii65; DOI: 10.1136/annrheumdis-2012-202195

Pages